This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)
Similar content being viewed by others Subjects Introduction As temperatures fall below the thermal neutral zone, body temperature is initially maintained by shivering thermogenesis via skeletal muscle and chronically by non-shivering thermogenesis in brown adipose tissue (BAT) 1,2,3
For patients who cannot take stimulants unlike phentermine, Contrave is non-stimulant
L., & Crapo, J
N-acetylcysteine improves coronary and peripheral vascular function
The analysis also indicated that the sterile mutants showed some unique gene expression changes, including collagen genes in glp-1(-) and fem-3(-) and transmembrane and unassigned genes in mog-3(-) (Fig